ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
70.90
0.30
(0.42%)
Closed December 21 11:30AM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
70.90
Bid
70.75
Ask
70.95
Volume
333,876
69.15 Day's Range 70.90
69.15 52 Week Range 104.40
Market Cap
Previous Close
70.60
Open
69.80
Last Trade
460
@
70.9
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
185,065
Shares Outstanding
74,704,751
Dividend Yield
4.94%
PE Ratio
12.67
Earnings Per Share (EPS)
5.6
Revenue
9.55B
Net Profit
418M

About Arkema

Sector
Chemicals & Chem Preps, Nec
Industry
Chemicals & Allied Products
Website
Headquarters
Colombes, Hauts-de-seine, Fra
Founded
2003
Arkema is listed in the Chemicals & Chem Preps sector of the Euronext with ticker AKE. The last closing price for Arkema was 70.60 €. Over the last year, Arkema shares have traded in a share price range of 69.15 € to 104.40 €.

Arkema currently has 74,704,751 shares outstanding. The market capitalization of Arkema is 5.27 € billion. Arkema has a price to earnings ratio (PE ratio) of 12.67.

AKE Latest News

Arkema Achieves a Milestone in Its Coating Products Portfolio Carbon Footprint Reduction with the Launch of Global Mass Balance Solutions for All Coatings Technologies

PARIS, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Arkema, a leader in Specialty Materials, set the groundwork for carbon footprint reduction across its Coating Solutions value chain in 2024, with a...

ARKEMA : RÉSULTATS DU 1ER TRIMESTRE 2022

Regulatory News: Arkema (Paris:AKE) a réalisé une excellente performance financière au premier trimestre, malgré la forte inflation des matières premières et de l’énergie et une certaine...

Arkema: Information Relating to the Combined Annual General Meeting of 19 May 2022

Regulatory News: Arkema (Paris:AKE): Arkema’s shareholders are invited to participate in the combined annual general meeting, which will be held on Thursday 19 May 2022 at 10 a.m. (Paris time...

ARKEMA : Déclaration relative au nombre total de droits de vote et d’actions prévue par l’article L.233-8 II du Code de commerce et l’article 223-16 du règlement général de l’Autorité des Marchés Financiers

Regulatory News: ARKEMA (Paris:AKE) : A la date du Nombre d’actions composant le capital Nombre théorique des droits de vote (y compris actions auto-détenues) Nombre réel de droits de...

Mise à disposition du document d’enregistrement universel 2021 d’arkema

Regulatory News: Arkema (Paris:AKE) annonce la publication de son Document d’enregistrement universel 2021. Le Document d’enregistrement universel 2021 a été déposé auprès de l’Autorité des...

Arkema : Déclaration des transactions sur actions propres réalisées du 07 mars au 11 mars 2022

Regulatory News: Conformément à la réglementation applicable, Arkema (Paris:AKE) déclare avoir effectué les opérations d'achat d'actions suivantes dans les conditions de l'article 5 §2 du...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-5.9-7.6822916666776.876.8569.1520337672.92091936DE
4-3.95-5.2772211088874.857969.1520394074.88169338DE
12-14.5-16.978922716685.488.469.1518506579.15626764DE
26-14.7-17.172897196385.688.469.1516263280.55319143DE
52-31.3-30.626223092102.2104.469.1514953987.46176432DE
156-47.25-39.9915361828118.15134.9569.1515922892.75386077DE
260-23.3-24.734607218794.2134.9542.518119892.58432618DE

AKE - Frequently Asked Questions (FAQ)

What is the current Arkema share price?
The current share price of Arkema is 70.90 €
How many Arkema shares are in issue?
Arkema has 74,704,751 shares in issue
What is the market cap of Arkema?
The market capitalisation of Arkema is EUR 5.27B
What is the 1 year trading range for Arkema share price?
Arkema has traded in the range of 69.15 € to 104.40 € during the past year
What is the PE ratio of Arkema?
The price to earnings ratio of Arkema is 12.67
What is the cash to sales ratio of Arkema?
The cash to sales ratio of Arkema is 0.55
What is the reporting currency for Arkema?
Arkema reports financial results in EUR
What is the latest annual turnover for Arkema?
The latest annual turnover of Arkema is EUR 9.55B
What is the latest annual profit for Arkema?
The latest annual profit of Arkema is EUR 418M
What is the registered address of Arkema?
The registered address for Arkema is 420, RUE D'ESTIENNE D'ORVES, COLOMBES, HAUTS-DE-SEINE, 92705
What is the Arkema website address?
The website address for Arkema is www.arkema.com
Which industry sector does Arkema operate in?
Arkema operates in the CHEMICALS & ALLIED PRODUCTS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TMBSZTME Pharma NV
0.02 €
(185.71%)
132.5k
MLGEQGentlemen S Equity SA
0.0175 €
(118.75%)
1.14k
ALCYBCybergun
0.0002 €
(100.00%)
17.54M
MLAAHAmatheon Agri Holding NV
0.0185 €
(54.17%)
40.1k
ALARFAdeunis
0.94 €
(28.77%)
5.27k
MLSMLSmalto
0.0125 €
(-37.50%)
2.34k
MLFTIFrance Tourisme Immobilier
0.025 €
(-35.90%)
56.77k
CNVCnova NV
0.209 €
(-19.62%)
26.38k
MLWEAWeaccess Group
0.382 €
(-16.96%)
5.95k
ALEUPEuroplasma
0.0353 €
(-15.95%)
3.16M
ATOAtos SE
0.0021 €
(0.00%)
2.71B
BCPBanco Comercial Portugues SA
0.4493 €
(-0.69%)
66.54M
ALHGLouis Hachette Group
1.3342 €
(4.87%)
52.04M
KPNKoninklijke KPN NV
3.509 €
(-1.21%)
26.9M
VIVVivendi SE
2.51 €
(2.41%)
26.39M

Discussion

View Full Feed
georgie18 georgie18 3 minutes ago
Nice...Thanks...🥳
Timing101 Timing101 3 minutes ago
Still Nothing , Strange
CSOL
SkyLimit2022 SkyLimit2022 3 minutes ago
zero82,

Thanks for another substantive comment 😶

https://nwbio.com/audio-of-nwbio-2023-annual-shareholders-meeting/

It’s a noteworthy publicly verifiable fact that NICE updated the published title to align with the MAA indications of both nGBM and
NWBO
Monroe1 Monroe1 4 minutes ago
No change showing yet. Holiday traffic probably.
ALSAF
Gmenfan Gmenfan 4 minutes ago
Maybe he'll return next year when Trump and his administration are in charge!
alertmeipp alertmeipp 5 minutes ago
Yeah, the Covid drug pivot really killed this company last couple years.

This tax loss season seems rather extreme, the volume has been 4x last year.

Some funds are bailing big time. RSV data isn’t bad
ENTA
downdraft downdraft 6 minutes ago
Great post!
AXXA
Good Sport Good Sport 6 minutes ago
Same warm wishes back.
I agree Chazz, I believe his hands are tied for the most part. Let's hope that is a good sign for things to come!
HDVY
Gmenfan Gmenfan 6 minutes ago
Ain't that the truth!!!!!!!!!!
Chiron Chiron 6 minutes ago
.0015
ASII
Chiron Chiron 7 minutes ago
.003 - .005 early Jan target
RDAR
Southern Gal Southern Gal 7 minutes ago
How's that sub half penny working out?
Soon, sub .003?
Those who profess to ignore are the least likely to do so.
SFRX
XMaster2023 XMaster2023 7 minutes ago
Investor 82 you are the one paid to mislead new investors on this board. You have no right to point out others talking about truth.
NWBO
al44 al44 9 minutes ago
Romance, RICO, and road trips: Fani Willis’s justice junket

By Charlton Allen


Fulton County faces the daunting task of rebuilding trust in its justice system. Whether it succeeds remains to be seen.

In Fulton County, Georgia, justice has taken a
Hoskuld Hoskuld 9 minutes ago
Hosai, that depends on how the number was arrived at by Google's AI. Impact factor is usually a calculation based on the number of times papers in the journal were cited by researchers over a 2 year period - which means impact factor can change significantly from year to year. I don't know if 9.2
AVXL
Johnnycombat10 Johnnycombat10 9 minutes ago
Outing bashing with the only limitations on their theory of speculation about PHIL is only speculation and not truth.
PHIL
glenn1919 glenn1919 9 minutes ago
IMRX........SLRX....MYNZ.......SRFM.........RDZN.......https://stockcharts.com/h-sc/ui?s=IMRX&p=D&yr=0&mn=2&dy=12&id=p84071410134
IMRX MYNZ RDZN
TheHound TheHound 10 minutes ago
News! https://www.globenewswire.com/fr/news-release/2016/12/22/901271/0/en/Cellceutix-Wishes-Shareholders-Happy-Holidays-Prepares-for-2017-Focused-on-Partnerships.html




Albeit old news. Very old news.
IPIX
blackhawks blackhawks 10 minutes ago
But, but, the cost of eggs!

U.S. economic growth revised up to 3.1% in third quarter
Source: axios

The revision suggests 2024 was yet another shocker year in which the U.S. economy surprised to the upside, as other major nations grappled with sluggish growth.
Investor082 Investor082 10 minutes ago
Not without reimbursement and hiring. No one trusts the lying crew.
NWBO
Backstabbed Backstabbed 10 minutes ago
You can't get delisted from OTC! wow... they just turn EM until they file 
VHAI
MrSmith18 MrSmith18 11 minutes ago
In my opinion, GS is definitely prepping something. Web sites don't come down unless the owner stops paying, (which I doubt happened here) or the owner, GS, took it down. Knowing GS's MO of antagonizing everyone with an element of surprise, my guess is that he's has a very big deal in the works. By
FORW GVSI SRNW
blackhawks blackhawks 11 minutes ago
But, but, the cost of eggs!

U.S. economic growth revised up to 3.1% in third quarter
Source: axios

The revision suggests 2024 was yet another shocker year in which the U.S. economy surprised to the upside, as other major nations grappled with sluggish growth.
Timing101 Timing101 11 minutes ago
Here you go
--
$EARI Very, Very Interesting. Leadership Change and the new Person Robert Morrissey (see the link(s) I always provide for any to research) has his company BRN (https://bigrednose.com)
Robert Morrissey LinkedIn File
https://linkedin.com/in/robert-morriss
EARI

Your Recent History

Delayed Upgrade Clock